1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2022, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 24, 13, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones
- Featured News & Press Releases
- Jul 12, 2022: Turn Therapeutics announces positive in-vivo data for non-melanoma skin cancer candidate
- Jul 11, 2022: MediWound announces positive initial data from its U.S. Phase I/II Study of MW005 for the treatment of basal cell carcinoma
- Apr 05, 2022: Lytix Biopharma receives milestone payment from Verrica Pharmaceuticals triggered by first patient dosed with LTX-315
- Apr 05, 2022: Verrica Pharmaceuticals announces first patient dosed in phase 2 study of LTX-315, a potential first-in-class oncolytic peptide-based immunotherapy, for the treatment of basal cell carcinoma
- Mar 28, 2022: At the 2022 AAD Annual Meeting, Senhwa presents positive initial data from clinical trial of Silmitasertib used to treat patients with advanced basal cell carcinoma
- Feb 23, 2022: Sirnaomics announces interim data from phase II clinical trial of STP705 for treatment of Cutaneous Basal Cell Carcinoma
- Feb 01, 2022: Biofrontera provides update on patient recruitment for phase III study for the treatment of sBCC with Ameluz-PDT
- Dec 16, 2021: Senhwa clinical data abstract for silmitasertib in patients with advanced basal cell carcinoma accepted for 2022 AAD Annual Meeting
- Nov 18, 2021: Verrica Pharmaceuticals announces FDA acceptance of its IND application for LTX-315, a potential first-in-class oncolytic peptide-based immunotherapy, for the treatment of basal cell carcinoma
- Oct 29, 2021: Libtayo (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients
- Aug 12, 2021: Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research
- Aug 06, 2021: Medivir: First-in-class histone deacetylase inhibitor gel shows promise for the treatment of patients with basal cell carcinoma
- Jul 26, 2021: MediWound announces initiation of U.S. phase I/II study of MW005 for the treatment of basal cell carcinoma
- Jun 25, 2021: Sanofi: Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
- Jun 07, 2021: MediWound announces peer-reviewed paper of a case series report of basal cell carcinoma published in the Open Dermatology Journal
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, 2022
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, 2022
- Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AiViva BioPharma Inc
- Amgen Inc
- Bayer AG
- Biofrontera AG
- Biomed
- Bristol-Myers Squibb Co
- Cannabis Science Inc
- Coegin Pharma AS
- Evotec SE
- Feldan Therapeutics Inc
- Genentech USA Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Ingenew Pharmaceuticals Inc
- Invion Ltd
- IO Biotech Inc
- Kintara Therapeutics Inc
- Kintor Pharmaceutical Ltd
- Laboratories Ojer Pharma SL
- Leo Pharma AS
- Lytix Biopharma AS
- Mayne Pharma Group Ltd
- MedC Biopharma Ltd
- Medicenna Therapeutics Corp
- MediGene AG
- Medivir AB
- MediWound Ltd
- Merck & Co Inc
- Morphogenesis Inc
- Neonc Technologies Inc
- NuCana Plc
- Oncorus Inc
- Ono Pharmaceutical Co Ltd
- Palvella Therapeutics LLC
- PellePharm Inc
- Philogen SpA
- Promontory Therapeutics Inc
- QBiotics Group Ltd
- Regeneron Pharmaceuticals Inc
- Replimune Ltd
- Senhwa Biosciences Inc
- Singh Biotechnology LLC
- Sirnaomics Ltd
- Transgene SA
- Turn Therapeutics Inc
- Varian Biopharmaceuticals Inc
- Xencor Inc
